Search Results
-
Post
Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic Cancer
...Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer,...
-
Post
Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
...called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing...
-
Post
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
...commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic...
-
Post
Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma
...Fields, or TTFields, for the treatment of solid tumor cancers. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase...
-
Post
Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology
...commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Novocure’s commercialized product, Optune, is approved for the treatment...
-
Post
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
...expires on June 30, 2016. “We remain committed to the global commercialization of Optune® for the treatment of glioblastoma, and to the execution of our clinical trial programs to develop...
-
Post
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
...expires on June 30, 2016. “We remain committed to the global commercialization of Optune® for the treatment of glioblastoma, and to the execution of our clinical trial programs to develop...
-
Post
Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report
...hazard ratio=0.66, p=0.004). In October 2015, the U.S. Food and Drug Administration approved Optune – a portable, non-invasive device that delivers TTFields – in combination with temozolomide for the treatment...
-
Post
Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data
...phase 3 clinical trial results in the Journal of the American Medical Association (JAMA). The EF-14 trial data show that treatment with Optune plus standard of care temozolomide significantly extended...
-
Post
NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option
...trials, research and development and continued commercialization of Optune and its future delivery systems. NovoCure shares trade on the NASDAQ Global Select Market under the symbol “NVCR.” J.P. Morgan Securities...